title: Selection of controls in the study of human neurodegenerative diseases in old age.
abstract: Human post-mortem brain tissue, mostly provided by brain banks, is precious because most human neurodegenerative diseases are restricted in their complete forms to human beings. However, the agonal state, post-mortem delay between death and tissue processing, variable vulnerability of chromatin, RNAs, proteins and metabolites can compromise the usability of the tissue material. Such factors must be considered and assessed in every experimental approach. The use of controls for comparative purposes to analyze diseased cases is crucial as the basic conditions of controls must be the same as those encountered in problem cases. Age, gender, region, hemisphere, and clear characterisation of objective neuropathological changes (e.g., Alzheimer's disease stages of Braak and Braak) in matching controls and problem cases must be considered in every study, and data must be clearly specified when presenting materials and methods in publications. Additional care must be taken regarding atypical neurodegenerative alterations, concomitant pathologies, and systemic diseases, together with drug consumption and treatments. The absence of neurological and mental symptoms and signs, although a sine qua non condition, is not sufficient to match control and problem cases for research.
authors.affiliation: Institute of Neuropathology, Bellvitge Biomedical Research Institute (IDIBELL), Centre for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Bellvitge University Hospital, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain, 8082ifa@gmail.com.
authors.forename: I
authors.initials: I
authors.lastname: Ferrer
mesh_terms: D000367:Age Factors; D000375:Aging / Q000473:pathology*; D001921:Brain / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D019636:Neurodegenerative Diseases / Q000473:pathology*; D011180:Postmortem Changes; D012737:Sex Factors; D013997:Time Factors; D014015:Tissue Banks
references.citation: Hum Mol Genet. 2004 Mar 15;13(6):609-16
references.pmid: 14734628
references.citation: Cell Tissue Bank. 2008 Sep;9(3):181-94
references.pmid: 18543077
references.citation: Cell Tissue Bank. 2012 Dec;13(4):597-606
references.pmid: 21922206
references.citation: Brain Res Mol Brain Res. 2003 Oct 21;118(1-2):60-71
references.pmid: 14559355
references.citation: Prog Neurobiol. 2012 Apr;97(1):38-51
references.pmid: 22459297
references.citation: Brain. 2010 Dec;133(Pt 12):3699-723
references.pmid: 20889584
references.citation: Curr Opin Neurol. 2003 Aug;16(4):459-63
references.pmid: 12869803
references.citation: Dement Geriatr Cogn Disord. 2008;26(4):343-50
references.pmid: 18849605
references.citation: Biol Psychiatry. 2004 Feb 15;55(4):346-52
references.pmid: 14960286
references.citation: Proteomics. 2008 Mar;8(6):1276-91
references.pmid: 18283663
references.citation: Cell Tissue Bank. 2011 Nov;12(4):289-97
references.pmid: 20652834
references.citation: Prog Brain Res. 2006;158:3-14
references.pmid: 17027689
references.citation: Neurobiol Dis. 2007 Jun;26(3):606-14
references.pmid: 17412603
references.citation: J Neuropathol Exp Neurol. 2007 Jan;66(1):35-46
references.pmid: 17204935
references.citation: Nat Neurosci. 2014 Mar;17(3):377-82
references.pmid: 24531307
references.citation: J Neuropathol Exp Neurol. 2010 Jan;69(1):70-81
references.pmid: 20010301
references.citation: Lancet Neurol. 2013 Nov;12(11):1096-105
references.pmid: 24074724
references.citation: Nat Rev Neurosci. 2009 Jan;10(1):70-8
references.pmid: 19050713